AusCann Group Holdings Ltd

Receive alerts
Market Cap:
$118.89 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 82


AusCann Group substantial shareholder lifts interest to 13.28%

Canopy Growth Corporation has exercised options valued at more than $1.535 million and now holds in excess of 42 million shares....

on 12/6/19

AusCann Group's new chief executive officer Ido Kanyon takes up role

The company is targeting the treatment of chronic pain in Australia while exploring global export opportunities and expansion into additional medical areas. ...

on 22/5/19

AusCann Group continues transition into pharmaceutical manufacturing and sales company

PCI Pharma has manufactured the first engineering batch of AusCann’s medical cannabis hard shell capsules for treatment of chronic pain, bringing the company closer to the release of its medicinal cannabis product line for clinical trials later this year. ...

on 30/4/19

AusCann Group’s MacLeman buys shares on-market

This purchase follows recent buying from the company’s board’s chairman....

on 28/3/19

AusCann Group chairman buys $58,238 worth of shares on-market

The purchase follows the recent appointment to CEO of ex Teva Pharmaceutical executive, Ido Kanyon....

on 12/3/19

Carnarvon Petroleum into S&P/ASX 300 – AC8, BGL, PAR into All Ordinaries

The rebalance changes are effective at the open of trading on March 18, 2019....

on 8/3/19

AusCann Group appoints Teva Pharmaceutical executive as new CEO

Ido Kanyon will replace interim CEO Dr Paul MacLeman on 22 May 2019....

on 25/2/19

AusCann Group secures supplier of cannabis resin for upcoming manufacturing

AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia....

on 21/2/19

AusCann Group on track to produce cannabinoid medicines this year

AusCann is a fully integrated early-mover pharmaceutical cannabinoid company....

on 11/2/19

AusCann Group’s chief operating and financial officer appointed joint company secretary

Quentin Megson will serve jointly in the role with existing company secretary Susan Hunter....

on 1/2/19

AusCann Group acquires R&D facility to develop cannabinoid product pipeline

The facility will support the development of existing and new cannabinoid formulations....

on 25/1/19

AusCann Group DayaCann joint venture to commence crop cultivation with Khiron

DayaCann is a 50:50 joint venture formed by AusCann and Chilean partner Fundación Daya....

on 22/1/19

AusCann Group shortlists candidates for chief executive officer role

Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board. ...

on 17/12/18

AusCann Group appoints PCI Pharma to manufacture first product line

The company's first product line is medicinal cannabis hard shell capsules....

on 13/11/18

AusCann Group releases education resources for medical cannabis awareness

The online education resources aim to bring awareness to medical professionals....

on 2/10/18

AusCann Group signs a medical cannabis deal with Columbia based Khiron Life Sciences

The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile....

on 1/10/18

AusCann Group appoints Paul MacLeman as executive director

AusCann is transitioning from a start-up company focused on product development to a pharmaceutical production and sales business....

on 27/9/18

AusCann Group commences trading in the US increasing global exposure

The company aims to release its first medicinal cannabis products in FY2019....

on 12/9/18

Auscann Group makes steady progress towards production of cannabinoid medicines

Auscann has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products....

on 31/8/18

AusCann Group well positioned as investors move in on medical cannabis sector

The company is a vertically integrated player thanks to early-mover partnerships....

on 30/8/18

Small and mid-cap companies will be showcased during inaugural ASX conference

The inaugural ASX Small and Mid-Cap Conference will be held in Sydney on Thursday, September 6....

on 22/8/18

AusCann Group pilot study reveals unique capsule for cannabinoid medicines

The study has developed a new hard capsule to deliver its cannabinoid medicines....

on 16/8/18

Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia

Many of the company's shareholders took this opportunity to increase their position. ...

on 9/8/18

AusCann Group to open $8 million share purchase plan this week

The SPP demonstrates that the company is willing to reward loyal shareholders....

on 16/7/18